Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

BACKGROUND: There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval. This study aimed to assess patients whose canakinumab dose interval was adjusted according to a specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavrul Kayaalp, Gülşah, Çağlayan, Şengül, Demirkan, Fatma Gül, Guliyeva, Vafa, Otar Yener, Gülçin, Öztürk, Kübra, Demir, Ferhat, Özdel, Semanur, Çakan, Mustafa, Sönmez, Hafize Emine, Sözeri, Betül, Aktay Ayaz, Nuray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666318/
https://www.ncbi.nlm.nih.gov/pubmed/37996934
http://dx.doi.org/10.1186/s12969-023-00925-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666318/
https://www.ncbi.nlm.nih.gov/pubmed/37996934
http://dx.doi.org/10.1186/s12969-023-00925-5

Ejemplares similares